Wimbledon forever: 8 ace homes with tennis courts

Caught Wimbledon fever? Check out these homes currently on the market with tennis courts

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

53.82

+2.15

(+4.16%)

At close: 04:00PM EDT

53.30

-0.52

(-0.97%)

After hours:

07:59PM EDT

Trade prices are not sourced from all markets

All

Motley Fool
3 Reasons to Buy Novavax and 1 to Sell
Novavax (NASDAQ: NVAX) is a pandemic stock. Now it's down to $50, and the company's market cap is under $4 billion. Here are three arguments for buying Novavax stock and one reason for why you might want to avoid these shares.
Motley Fool
5 Unique Stocks That Can Generate Transformational Wealth
As much as you might hate to hear this, stock market corrections and bear markets are a perfectly normal part of the investing cycle. Including the current bear market decline that the benchmark S&P 500 and tech-focused Nasdaq Composite are navigating their way through, the broader market has dropped by a double-digit percentage, on average, every 1.85 years since the beginning of 1950. Despite corrections being commonplace, the amount of time Wall Street spends in a bull market handily outpaces periods of pessimism.
Motley Fool
Why Sanofi May Be a Frontrunner in Endemic COVID-19
Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.